Your browser is no longer supported. Please, upgrade your browser.
Settings
NMRD Nemaura Medical Inc. daily Stock Chart
NMRD [NASD]
Nemaura Medical Inc.
Index- P/E- EPS (ttm)-0.03 Insider Own67.00% Shs Outstand205.11M Perf Week2.14%
Market Cap391.76M Forward P/E- EPS next Y- Insider Trans- Shs Float59.06M Perf Month-10.33%
Income-2.90M PEG- EPS next Q- Inst Own0.02% Short Float0.27% Perf Quarter-15.38%
Sales- P/S- EPS this Y-60.20% Inst Trans179.85% Short Ratio1.05 Perf Half Y-34.36%
Book/sh0.01 P/B191.00 EPS next Y- ROA-50.80% Target Price- Perf Year-60.21%
Cash/sh0.02 P/C103.09 EPS next 5Y- ROE-84.90% 52W Range1.57 - 6.80 Perf YTD-62.55%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-71.91% Beta-
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low21.73% ATR0.18
Employees8 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)41.61 Volatility12.17% 9.31%
OptionableNo Debt/Eq0.00 EPS Q/Q-189.60% Profit Margin- Rel Volume0.06 Prev Close1.86
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume151.37K Price1.91
Recom- SMA20-3.00% SMA50-17.72% SMA200-39.74% Volume8,508 Change2.69%
Nov-14-18 09:00AM  Nemaura Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum GlobeNewswire -5.04%
Nov-12-18 09:00AM  Nemaura Medical to Present at the Stifel 2018 Healthcare Conference GlobeNewswire
Nov-08-18 09:00AM  Nemaura Medical Inc. Reports Second Quarter 2018 Financial Results GlobeNewswire +6.38%
Nov-07-18 09:00AM  Nemaura Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT® GlobeNewswire
Oct-22-18 08:00AM  Nemaura to Host Investor Webinar on October 23rd 2018 to Provide Update on Recent Developments GlobeNewswire +6.10%
Sep-25-18 08:00AM  Nemaura Reports Positive Zero Finger-Stick Calibration Data for SugarBEAT® Continuous Glucose Monitor GlobeNewswire
Sep-18-18 08:00AM  Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar GlobeNewswire +5.83%
Sep-13-18 09:19AM  Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday Motley Fool +19.93%
Sep-12-18 08:00AM  Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT® FDA Clinical Trial GlobeNewswire +32.69%
Aug-09-18 08:00AM  Nemaura Medical Inc. Reports First Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 08:00AM  Nemaura Initiates US FDA Studies, and Reports Positive Interim Data from Home-Use Portion of Study GlobeNewswire +6.94%
Jul-17-18 08:00AM  Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch Business Wire +13.53%
Jun-13-18 09:30AM  Nemaura Medical Inc. Reports Full Year Financial Results Business Wire +8.98%
May-30-18 09:30AM  Nemaura Medical Signs Joint Collaboration Agreement for European Commercialization Business Wire
May-15-18 09:30AM  Nemaura Medical to Present at the UBS Global Healthcare Conference Business Wire
Apr-09-18 09:30AM  Nemaura Medical Appoints Bashir Timol Chief Business Officer Business Wire +23.37%
Mar-28-18 11:05AM  Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel Business Wire
Mar-06-18 09:00AM  Nemaura Medical to Ring the Nasdaq Closing Bell Business Wire
Mar-05-18 10:50AM  CORRECTING and REPLACING -- Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
10:00AM  Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Mar-01-18 04:18PM  Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch Business Wire
Feb-09-18 01:17PM  Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results Business Wire
Jan-31-18 01:20PM  Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program Business Wire +7.24%
Jan-23-18 09:00AM  Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018 Business Wire +6.38%
Dec-21-17 10:00AM  Nemaura Announces Completion of SugarBEAT® European Clinical Trial Programme and Positive Interim Results Business Wire
Dec-06-17 09:00AM  Nemaura Announces Successful SugarBEAT® Interim Precision Study Results Business Wire
Nov-02-17 09:47AM  Nemaura Medical Inc. Reports Second Quarter 2017 Financial Results Business Wire
Sep-26-17 09:00AM  WallStreet Research Announces Availability of Corporate Profile Coverage on Nemaura Medical, Inc. Business Wire
Sep-21-17 09:00AM  Nemaura Announces Successful Interim Results for SugarBEAT® European Clinical Trials Business Wire
Aug-29-17 11:24AM  Nemaura Develops Medical Grade SugarBEAT® Android App for Diabetes Management Business Wire
Aug-15-17 12:47PM  Nemaura Signs Heads of Terms for sugarBEAT® with Device Technologies for Australia and New Zealand Business Wire
Aug-09-17 09:00AM  Nemaura Medical Inc. Reports First Quarter 2017 Financial Results Business Wire
Aug-03-17 09:00AM  Nemaura Appoints Thomas Moore to Board of Directors as Independent Director Business Wire -14.58%
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes specialty medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. The company was founded in 2009 and is headquartered in Loughborough, the United Kingdom.